Demographic and Clinical Characteristics of Mpox in Persons Who Had Previously Received 1 Dose of JYNNEOS Vaccine and in Unvaccinated Persons — 29 U.S. Jurisdictions, May 22–September 3, 2022
Jennifer L. Farrar, Nathaniel M. Lewis, Kennedy Houck, Michelle Canning, Amy Fothergill, Amanda B. Payne, Adam L. Cohen, J. C. Vance, Bridget Brassil, Erin Youngkin, Bailey Glenn, Anil T. Mangla, Nikki Kupferman, Katharine Saunders, Cristina Meza, Dawn Nims, Susan Soliva, Brandon Blouse, Tiffany Henderson, Emily Banerjee, Brooklyn White, Rachael Birn, Anna Stadelman, Meaghan Abrego, Meagan McLafferty, Michael Eberhart, Michael Pietrowski, Sandra Miranda De León, Emma Creegan, Abdoulaye Diédhiou, Caleb Wiedeman, Jade Murray-Thompson, Elizabeth McCarty, Jessica Marcinkevage, Anna Kocharian, Elizabeth Torrone, Logan C. Ray, Daniel C. Payne, Mpox Cases in Vaccinated Persons Team, Mpox Cases in Vaccinated Persons Team, Matthew M. Cole, Lauren E. Roper, Hazel J. Shah, Louise McNitt, Stephanie Gretsch, Melissa Pike, Patricia Firmender, Will Still, Jamie Ahlers, Aman Punwani, Komal Patel, Nam-Kyu Cho, Marcia Pearlowitz, Petra Schubert, Ryan E. Malosh, Sydney Kuramoto, Matthew Donahue, Miranda Durham, Charlotte DelBarba, Kelly Cogswell, Julie Miedlar, Dana Perella, Julian D. Cordero Calderon, Taidy Perez, Jacqueline Logan, Abigail Collingwood, Naihlah Smith, Rachel Klos
Abstract
6,605 (45.5%) had available vaccination information and were included in the analysis. Among included cases, 276 (4.2%) were among persons who had received 1 dose of vaccine ≥14 days before illness onset. Mpox cases that occurred in these vaccinated persons were associated with lower percentage of hospitalization (2.1% versus 7.5%), fever, headache, malaise, myalgia, and chills, compared with cases in unvaccinated persons. Although 1 dose of JYNNEOS vaccine offers some protection from disease, mpox infection can occur after receipt of 1 dose, and the duration of protection conferred by 1 dose is unknown. Providers and public health officials should therefore encourage persons at risk for acquiring mpox to complete the 2-dose vaccination series and provide guidance and education regarding nonvaccine-related prevention strategies (4).